{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:43:45Z","timestamp":1792172625850,"version":"4.4.0"},"reference-count":166,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty Research Support of Georgetown University Medical Center (GUMC)","award":["N01-AI-05399"],"award-info":[{"award-number":["N01-AI-05399"]}]},{"name":"Faculty Research Support of Georgetown University Medical Center (GUMC)","award":["HHSN272201000011I"],"award-info":[{"award-number":["HHSN272201000011I"]}]},{"name":"Faculty Research Support of Georgetown University Medical Center (GUMC)","award":["HHSN27200001 (D01)"],"award-info":[{"award-number":["HHSN27200001 (D01)"]}]},{"name":"Faculty Research Support of Georgetown University Medical Center (GUMC)","award":["HHSN27200002 (D06)"],"award-info":[{"award-number":["HHSN27200002 (D06)"]}]},{"name":"Faculty Research Support of Georgetown University Medical Center (GUMC)","award":["HHSN2720004 (D13)"],"award-info":[{"award-number":["HHSN2720004 (D13)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Infection with hepatitis B virus (HBV) is responsible for the increasing global hepatitis burden, with an estimated 296 million people being carriers and living with the risk of developing chronic liver disease and cancer. While the current treatment options for chronic hepatitis B (CHB), including oral nucleos(t)ide analogs and systemic interferon-alpha, are deemed suboptimal, the path to finding an ultimate cure for this viral disease is rather challenging. The lack of suitable laboratory animal models that support HBV infection and associated liver disease progression is one of the major hurdles in antiviral drug development. For more than four decades, experimental infection of the Eastern woodchuck with woodchuck hepatitis virus has been applied for studying the immunopathogenesis of HBV and developing new antiviral therapeutics against CHB. There are several advantages to this animal model that are beneficial for performing both basic and translational HBV research. Previous review articles have focused on the value of this animal model in regard to HBV replication, pathogenesis, and immune response. In this article, we review studies of drug development and preclinical evaluation of direct-acting antivirals, immunomodulators, therapeutic vaccines, and inhibitors of viral entry, gene expression, and antigen release in the woodchuck model of CHB since 2014 until today and discuss their significance for clinical trials in patients.<\/jats:p>","DOI":"10.3390\/v14081711","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T23:33:01Z","timestamp":1659569581000},"page":"1711","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recent Drug Development in the Woodchuck Model of Chronic Hepatitis B"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-0374","authenticated-orcid":false,"given":"Manasa","family":"Suresh","sequence":"first","affiliation":[{"name":"Georgetown University Medical Center, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-4084","authenticated-orcid":false,"given":"Stephan","family":"Menne","sequence":"additional","affiliation":[{"name":"Georgetown University Medical Center, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1099\/jgv.0.001415","article-title":"ICTV Virus Taxonomy Profile: Hepadnaviridae","volume":"101","author":"Magnius","year":"2020","journal-title":"J. Gen. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"a021386","DOI":"10.1101\/cshperspect.a021386","article-title":"Hepadnavirus Genome Replication and Persistence","volume":"5","author":"Hu","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans","volume":"46","author":"Schulze","year":"2007","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.1811064116","article-title":"Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization","volume":"116","author":"Iwamoto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dias, J.D., Sarica, N., and Neuveut, C. (2021). Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation. Viruses, 13.","DOI":"10.3390\/v13050757"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hep.31720","article-title":"Characterization and Application of Precore\/Core-Related Antigens in Animal Models of Hepatitis B Virus Infection","volume":"74","author":"Hong","year":"2021","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e01695-20","DOI":"10.1128\/JVI.01695-20","article-title":"Characterization of Hepatitis B Precore\/Core-Related Antigens","volume":"95","author":"Hong","year":"2021","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: The virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","article-title":"Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate","volume":"29","author":"Summers","year":"1982","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"ref_14","first-page":"100034","article-title":"Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery","volume":"1","author":"Zhao","year":"2020","journal-title":"Innovation"},{"key":"ref_15","unstructured":"World Health Organization (2022, June 10). Hepatitis, B. 2022. Available online: https:\/\/wwwwhoint\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_16","unstructured":"(2022, June 10). Global Hepatitis Report, 2017. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241565455."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coviro.2016.06.004","article-title":"Current treatments for chronic hepatitis B virus infections","volume":"18","author":"Zoulim","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Costa, J.B., Dufeu-Duchesne, T., Leroy, V., Bertucci, I., Bouvier-Alias, M., Pouget, N., Brevot-Lutton, O., Bourliere, M., Zoulim, F., and Plumas, J. (2016). Pegylated Interferon \u03b1-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158297"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"733364","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and Hepatitis B: Current and Future Perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e01032-19","DOI":"10.1128\/JVI.01032-19","article-title":"Revisiting Hepatitis B Virus: Challenges of Curative Therapies","volume":"93","author":"Hu","year":"2019","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3748\/wjg.v13.i1.104","article-title":"The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection","volume":"13","author":"Menne","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bellezza, C.A., Sexton, S.S., Curtin, L.I., Concannon, P.W., Baldwin, B.H., Graham, L.A., Hornbuckle, W.E., Roth, L., and Tennant, B.C. (2015). The Laboratory Woodchuck (Marmota monax). Laboratory Animal Medicine, Academic Press.","DOI":"10.1016\/B978-0-12-409527-4.00008-0"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fimmu.2020.00853","article-title":"Diverse Virus and Host-Dependent Mechanisms Influence the Systemic and Intrahepatic Immune Responses in the Woodchuck Model of Hepatitis B","volume":"11","author":"Michalak","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1073\/pnas.75.9.4533","article-title":"A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks","volume":"75","author":"Summers","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hep.510310128","article-title":"Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection","volume":"31","author":"Cote","year":"2000","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1073\/pnas.77.4.1842","article-title":"Isolation, characterization, and comparison of recombinant DNAs derived from genomes of human hepatitis B virus and woodchuck hepatitis virus","volume":"77","author":"Cummings","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1073\/pnas.84.3.866","article-title":"Hepatocarcinogenicity of the woodchuck hepatitis virus","volume":"84","author":"Popper","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4251\/wjgo.v13.i6.509","article-title":"Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer","volume":"13","author":"Suresh","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"a021469","DOI":"10.1101\/cshperspect.a021469","article-title":"The Chimpanzee Model for Hepatitis B Virus Infection","volume":"5","author":"Wieland","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"715450","DOI":"10.3389\/fmicb.2021.715450","article-title":"Animal Models for the Study of Hepatitis B Virus Pathobiology and Immunity: Past, Present, and Future","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/s41467-017-01953-y","article-title":"Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques","volume":"8","author":"Burwitz","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1038\/s41467-022-30593-0","article-title":"Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity","volume":"13","author":"Biswas","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.25730","article-title":"Transcriptomic analysis of the woodchuck model of chronic hepatitis B","volume":"56","author":"Fletcher","year":"2012","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Liu, Y., Wang, B., Wang, L., Vikash, V., Wang, Q., Roggendorf, M., Lu, M., Yang, D., and Liu, J. (2016). Transcriptome Analysis and Comparison of Marmota monax and Marmota himalayana. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165875"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1534\/g3.119.400413","article-title":"The Genome Sequence of the Eastern Woodchuck (Marmota monax)\u2014A Preclinical Animal Model for Chronic Hepatitis B","volume":"9","author":"Alioto","year":"2019","journal-title":"G3 Genes|Genomes|Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.12688\/f1000research.25970.1","article-title":"The genome of the American groundhog, Marmota monax","volume":"9","author":"Puiu","year":"2020","journal-title":"F1000Research"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00654-08","article-title":"Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection","volume":"52","author":"Menne","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1128\/AAC.42.12.3209","article-title":"Efficacy of the Carbocyclic 2\u2032-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection","volume":"42","author":"Genovesi","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1086\/324003","article-title":"Long-Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection","volume":"184","author":"Colonno","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1053\/he.2000.5982","article-title":"Treatment of chronic woodchuck hepatitis virus infection in the eastern woodchuck (marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans","volume":"31","author":"Korba","year":"2000","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.79.15.9369-9380.2005","article-title":"Stealth and Cunning: Hepatitis B and Hepatitis C Viruses","volume":"79","author":"Wieland","year":"2005","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jhep.2016.01.028","article-title":"The role of innate immunity in the immunopathology and treatment of HBV infection","volume":"64","author":"Maini","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/JVI.01263-15","article-title":"Viral DNA-Dependent Induction of Innate Immune Response to Hepatitis B Virus in Immortalized Mouse Hepatocytes","volume":"90","author":"Cui","year":"2016","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","article-title":"The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus","volume":"42","author":"Sato","year":"2015","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4254\/wjh.v8.i17.716","article-title":"Innate immune targets of hepatitis B virus infection","volume":"8","author":"Zou","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2542","article-title":"New Insights into how HBV Manipulates the Innate Immune Response to Establish Acute and Persistent Infection","volume":"18","author":"Revill","year":"2013","journal-title":"Antivir. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","article-title":"Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver","volume":"154","author":"Suslov","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","article-title":"Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection","volume":"137","author":"Dunn","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","article-title":"Hepatitis B Virus\u2013Specific and Global T-Cell Dysfunction in Chronic Hepatitis B","volume":"150","author":"Park","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection","volume":"159","author":"Gill","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2019.07.015","article-title":"Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B","volume":"72","author":"Salimzadeh","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/jmv.20019","article-title":"Kinetics of viremia and acute liver injury in relation to outcome of neonatal woodchuck hepatitis virus infection","volume":"72","author":"Wang","year":"2004","journal-title":"J. Med. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1128\/JVI.01022-08","article-title":"Intrahepatic Expression of Genes Affiliated with Innate and Adaptive Immune Responses Immediately after Invasion and during Acute Infection with Woodchuck Hepadnavirus","volume":"82","author":"Guy","year":"2008","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1128\/JVI.76.4.1769-1780.2002","article-title":"Deficiencies in the Acute-Phase Cell-Mediated Immune Response to Viral Antigens Are Associated with Development of Chronic Woodchuck Hepatitis Virus Infection following Neonatal Inoculation","volume":"76","author":"Menne","year":"2002","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Suresh, M., Czerwinski, S., Murreddu, M.G., Kallakury, B.V., Ramesh, A., Gudima, S.O., and Menne, S. (2019). Innate and adaptive immunity associated with resolution of acute woodchuck hepatitis virus infection in adult woodchucks. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1008248"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.1128\/JVI.00984-15","article-title":"Infection Patterns Induced in Naive Adult Woodchucks by Virions of Woodchuck Hepatitis Virus Collected during either the Acute or Chronic Phase of Infection","volume":"89","author":"Freitas","year":"2015","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"721975","DOI":"10.3389\/fimmu.2021.721975","article-title":"HBV-Specific CD8+ T-Cell Tolerance in the Liver","volume":"12","author":"Baudi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: Current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/jhep.2003.50154","article-title":"Role of type 1 versus type 2 immune responses in liver during the onset of chronic woodchuck hepatitis virus infection","volume":"37","author":"Wang","year":"2003","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1128\/JVI.72.7.6083-6091.1998","article-title":"T-Cell Response to Woodchuck Hepatitis Virus (WHV) Antigens during Acute Self-Limited WHV Infection and Convalescence and after Viral Challenge","volume":"72","author":"Menne","year":"1998","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"100398","DOI":"10.1016\/j.jhepr.2021.100398","article-title":"Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV","volume":"4","author":"Vanwolleghem","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/hep.31112","article-title":"Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes","volume":"72","author":"Zhang","year":"2020","journal-title":"Hepatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clim.2008.04.006","article-title":"Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients","volume":"128","author":"Chen","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Lauterbach-Rivi\u00e8re, L., Bergez, M., M\u00f6nch, S., Qu, B., Riess, M., Vondran, F.W.R., Liese, J., Hornung, V., Urban, S., and K\u00f6nig, R. (2020). Hepatitis B Virus DNA is a Substrate for the cGAS\/STING Pathway but is not Sensed in Infected Hepatocytes. Viruses, 12.","DOI":"10.3390\/v12060592"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3389\/fimmu.2021.713420","article-title":"Involvement of Innate Immune Receptors in the Resolution of Acute Hepatitis B in Woodchucks","volume":"12","author":"Suresh","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Korolowicz, K.E., Suresh, M., Li, B., Huang, X., Yon, C., Kallakury, B.V., Lee, K.-P., Park, S., Kim, Y.-W., and Menne, S. (2021). Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks. Cells, 10.","DOI":"10.3390\/cells10092321"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/hep4.1502","article-title":"Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-\u03b1 in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus","volume":"4","author":"Menne","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2017.10.022","article-title":"Activity of nucleic acid polymers in rodent models of HBV infection","volume":"149","author":"Motter","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5009\/gnl17233","article-title":"Immunotherapy for Chronic Hepatitis B Virus Infection","volume":"12","author":"Bertoletti","year":"2018","journal-title":"Gut Liver"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2018.01.008","article-title":"Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B","volume":"30","author":"Suslov","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Fletcher, S.P., Chin, D.J., Gruenbaum, L., Bitter, H., Rasmussen, E., Ravindran, P., Swinney, D.C., Birzele, F., Schmucki, R., and Lorenz, S.H. (2015). Intrahepatic Transcriptional Signature Associated with Response to Interferon-\u03b1 Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005103"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2015.02.048","article-title":"Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I","volume":"63","author":"Berraondo","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep4.1397","article-title":"Liver-Targeted Toll-Like Receptor 7 Agonist Combined With Entecavir Promotes a Functional Cure in the Woodchuck Model of Hepatitis B Virus","volume":"3","author":"Korolowizc","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"884113","DOI":"10.3389\/fimmu.2022.884113","article-title":"Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B","volume":"13","author":"Wildum","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B","volume":"73","author":"Daffis","year":"2020","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2015.11.001","article-title":"Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection","volume":"125","author":"Meng","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Korolowicz, K.E., Suresh, M., Li, B., Huang, X., Yon, C., Leng, X., Kallakury, B.V., Tucker, R.D., and Menne, S. (2021). Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B. Viruses, 13.","DOI":"10.3390\/v13040648"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Suresh, M., Korolowicz, K.E., Balarezo, M., Iyer, R.P., Padmanabhan, S., Cleary, D., Gimi, R., Sheri, A., Yon, C., and Kallakury, B.V. (2017). Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169631"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Balsitis, S., Gali, V., Mason, P.J., Chaniewski, S., Levine, S.M., Wichroski, M.J., Feulner, M., Song, Y., Granaldi, K., and Loy, J.K. (2018). Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190058"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., M\u00f6ller, I., Seiz, P., Glebe, D., and Wang, B. (2014). Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003856"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.03.008","article-title":"Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review","volume":"83","author":"Chen","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.25954","article-title":"Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B","volume":"57","author":"Fletcher","year":"2013","journal-title":"Hepatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.24306","article-title":"Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties","volume":"53","author":"Fioravanti","year":"2011","journal-title":"Hepatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1572-0241.2006.01006.x","article-title":"Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator on Treatment of Chronic Hepatitis B","volume":"102","author":"Sarin","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nri3446","article-title":"The history of Toll-like receptors\u2014Redefining innate immunity","volume":"13","author":"Golenbock","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1189\/jlb.4MR0316-108R","article-title":"Emerging roles of the processing of nucleic acids and Toll-like receptors in innate immune responses to nucleic acids","volume":"101","author":"Miyake","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lfs.2016.06.026","article-title":"The link between TLR7 signaling and hepatitis B virus infection","volume":"158","author":"Sepehri","year":"2016","journal-title":"Life Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3851\/IMP2548","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of Gs-9620, An Oral Toll-Like Receptor 7 Agonist","volume":"18","author":"Lopatin","year":"2013","journal-title":"Antivir. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jvh.12942","article-title":"Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment","volume":"25","author":"Agarwal","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/cts.12791","article-title":"A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers","volume":"13","author":"Luk","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1016\/S0168-8278(18)31878-6","article-title":"Preclinical mechanistic and efficacy evaluation of a novel small molecule TLR7 agonist RO7020531 for the treatment of chronic hepatitis B","volume":"68","author":"Dai","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0168-8278(18)30253-8","article-title":"Combination treatment of a TLR7 agonist RO7020531and a capsid assembly modulator RO7049389 achieved sustainable viral loadsuppression and HBsAg loss in an AAV-HBV mouse model","volume":"68","author":"Dai","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"105196","DOI":"10.1016\/j.antiviral.2021.105196","article-title":"JNJ-64794964 (AL-034\/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV\/HBV mice via non-cytolytic mechanisms","volume":"196","author":"Herschke","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/13543784.2021.1873275","article-title":"Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals","volume":"30","author":"Hu","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Espinoza, I., and Guerrero-Plata, A. (2022). The Relevance of TLR8 in Viral Infections. Pathogens, 11.","DOI":"10.3390\/pathogens11020134"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"eaaw1347","DOI":"10.1126\/scisignal.aaw1347","article-title":"TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection","volume":"12","author":"Dhaliwal","year":"2019","journal-title":"Sci. Signal."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Jo, J., Tan, A.T., Ussher, J.E., Sandalova, E., Tang, X.-Z., Tan-Garcia, A., To, N., Hong, M., Chia, A., and Gill, U.S. (2014). Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004210"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators","volume":"74","author":"Amin","year":"2020","journal-title":"Hepatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"735913","DOI":"10.3389\/fimmu.2021.735913","article-title":"Follicular Helper T (TFH) Cell Targeting by TLR8 Signaling For Improving HBsAg-Specific B Cell Response In Chronic Hepatitis B Patients","volume":"12","author":"Ayithan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.onc.1210911","article-title":"Toll-like receptor 9 (TLR9) agonists in the treatment of cancer","volume":"27","author":"Krieg","year":"2008","journal-title":"Oncogene"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14728222.2010.501333","article-title":"Targeting the TLR9\u2013MyD88 pathway in the regulation of adaptive immune responses","volume":"14","author":"Huang","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00063030-200721060-00006","article-title":"Therapeutic Applications of Synthetic CpG Oligodeoxynucleotides as TLR9 Agonists for Immune Modulation","volume":"21","author":"Jurk","year":"2007","journal-title":"BioDrugs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10096-012-1780-x","article-title":"Therapeutic immunomodulation using a virus\u2014the potential of inactivated orf virus","volume":"32","author":"Weber","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1099\/vir.0.19138-0","article-title":"Inactivated parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus","volume":"84","author":"Weber","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Paulsen, D., Urban, A., Knorr, A., Hirth-Dietrich, C., Siegling, A., Volk, H.-D., Mercer, A.A., Limmer, A., Schumak, B., and Knolle, P.A. (2013). Inactivated Orf Virus Shows Antifibrotic Activity and Inhibits Human Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Replication in Preclinical Models. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074605"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Paulsen, D., Weber, O., Ruebsamen-Schaeff, H., Tennant, B.C., and Menne, S. (2015). AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144383"},{"key":"ref_121","first-page":"92A","article-title":"Pan-genotypic anti-HCV activity of SB 9200 assessed in the \u201ccapture-fusion\u201d replication assay","volume":"58","author":"Cunningham","year":"2013","journal-title":"Hepatology"},{"key":"ref_122","unstructured":"Iyer, R.P., Sheri, R., Pandey, R.K., Padmanabhan, S., Korba, B.E., and Bose, S. (2014, January 12\u201316). Activation of intracellular viral sensors by the anti-hepatitis Agent SB 9200\u2014Implications for broad-spectrum antiviral activity. Proceedings of the 27th International Conference on Antiviral Research 2014, Raleigh, NC, USA."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.coph.2005.04.019","article-title":"Nucleotide analogs as novel anti-hepatitis B virus agents","volume":"5","author":"Iyer","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bmcl.2010.01.010","article-title":"Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs","volume":"20","author":"Coughlin","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1124\/dmd.111.044446","article-title":"Metabolism, Pharmacokinetics, Tissue Distribution, and Stability Studies of the Prodrug Analog of an Anti-Hepatitis B Virus Dinucleoside Phosphorothioate","volume":"40","author":"Coughlin","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1128\/AAC.48.6.2318-2320.2004","article-title":"Anti-Hepatitis B Virus Activity of ORI-9020, a Novel Phosphorothioate Dinucleotide, in a Transgenic Mouse Model","volume":"48","author":"Iyer","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Korolowicz, K.E., Iyer, R.P., Czerwinski, S., Suresh, M., Yang, J., Padmanabhan, S., Sheri, A., Pandey, R.K., Skell, J., and Marquis, J.K. (2016). Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161313"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","article-title":"Switching to PegIFN\u03b1-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.30897","article-title":"Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression","volume":"71","author":"Yang","year":"2020","journal-title":"Hepatology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.04321-14","article-title":"STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus","volume":"59","author":"Guo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41419-020-03284-1","article-title":"Hepatitis B virus particles activate B cells through the TLR2\u2013MyD88\u2013mTOR axis","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.3389\/fmicb.2018.03007","article-title":"Differential Expression of Woodchuck Toll-Like Receptors 1\u201310 in Distinct Forms of Infection and Stages of Hepatitis in Experimental Hepatitis B Virus Infection","volume":"9","author":"Williams","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11596-016-1588-5","article-title":"Molecular cloning, characterization and expression analysis of woodchuck retinoic acid-inducible gene I","volume":"36","author":"Yan","year":"2016","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"745802","DOI":"10.3389\/fimmu.2021.745802","article-title":"Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects","volume":"12","author":"Suresh","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Zhang, E., Zhang, X., Liu, J., Wang, B., Tian, Y., Kosinska, A.D., Ma, Z., Xu, Y., Dittmer, U., and Roggendorf, M. (2011). The Expression of PD-1 Ligands and Their Involvement in Regulation of T Cell Functions in Acute and Chronic Woodchuck Hepatitis Virus Infection. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026196"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2017.03.011","article-title":"Therapeutic vaccination for chronic hepatitis B","volume":"23","author":"Kosinska","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.patbio.2010.04.005","article-title":"The woodchuck: A model for therapeutic vaccination against hepadnaviral infection","volume":"58","author":"Roggendorf","year":"2010","journal-title":"Pathol. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Kosinska, A.D., Zhang, E., Johrden, L., Liu, J., Seiz, P.L., Zhang, X., Ma, Z., Kemper, T., Fiedler, M., and Glebe, D. (2013). Combination of DNA Prime\u2014Adenovirus Boost Immunization with Entecavir Elicits Sustained Control of Chronic Hepatitis B in the Woodchuck Model. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003391"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.virol.2008.11.012","article-title":"Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression","volume":"384","author":"Meng","year":"2009","journal-title":"Virology"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Meng, Z., Zhang, X., Wu, J., Pei, R., Xu, Y., Yang, D., Roggendorf, M., and Lu, M. (2013). RNAi Induces Innate Immunity through Multiple Cellular Signaling Pathways. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064708"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/jmv.26063","article-title":"Compassionate use of hzVSF-v13 in two patients with severe COVID-19","volume":"92","author":"Kang","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_147","unstructured":"Kim, Y.W., Kim, Y.J., Hong, H.J., Park, S.J., Kim, M.W., and Park, S. (2016). An Antibody or Peptide Specifically Binding to Peptide Derived from Vimentin. (10201600726972016), Korea Patent."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e07586","DOI":"10.1016\/j.heliyon.2021.e07586","article-title":"Humanized virus-suppressing factor inhibits hepatitis B virus infection by targeting viral cell entry","volume":"7","author":"Miyakawa","year":"2021","journal-title":"Heliyon"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"103499","DOI":"10.1016\/j.ebiom.2021.103499","article-title":"Functional cure of chronic hepatitis B\u2014Predictable?","volume":"70","author":"Gerlich","year":"2021","journal-title":"eBioMedicine"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1021\/acs.jmedchem.8b01245","article-title":"Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action","volume":"61","author":"Han","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2017.10.014","article-title":"A novel orally available small molecule that inhibits hepatitis B virus expression","volume":"68","author":"Mueller","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acsmedchemlett.1c00228","article-title":"Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation","volume":"12","author":"Hwang","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection","volume":"5","author":"Vaillant","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Al-Mahtab, M., Bazinet, M., and Vaillant, A. (2016). Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156667"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): A non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Noordeen, F., Scougall, C.A., Grosse, A., Qiao, Q., Ajilian, B.B., Reaiche-Miller, G., Finnie, J., Werner, M., Broering, R., and Schlaak, J.F. (2015). Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140909"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S0168-8278(15)30133-1","article-title":"O114: Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-CA","volume":"62","author":"Jansen","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 Agonist Increases Responses of Hepatitis B Virus\u2013Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3851\/IMP3363","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of Selgantolimod, an Oral Toll-Like Receptor 8 Agonist: A Phase Ia Study in Healthy Subjects","volume":"25","author":"Reyes","year":"2020","journal-title":"Antivir. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/hep.31795","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"},{"key":"ref_161","first-page":"S757","article-title":"Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B","volume":"75","author":"Harry","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30650-4","article-title":"Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: A phase 2 study","volume":"73","author":"Gane","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1016\/S0618-8278(19)30944-2","article-title":"FRI-199-First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis","volume":"70","author":"Addy","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S0618-8278(19)30084-2","article-title":"GS-12-Ascending dose cohort study of inarigivir\u2014A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial","volume":"70","author":"Yuen","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_165","unstructured":"(2022, June 10). Spring Bank Halts Development of Inarigivir for Hepatitis B. Available online: https:\/\/www.clinicaltrialsarena.com\/news\/spring-bank-stops-inarigivir-hbv\/."},{"key":"ref_166","first-page":"767","article-title":"Liver sampling: A vital window into HBV pathogenesis on the path to functional cure","volume":"67","author":"Gill","year":"2018","journal-title":"Gut"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/8\/1711\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:03:44Z","timestamp":1760141024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/8\/1711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":166,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["v14081711"],"URL":"https:\/\/doi.org\/10.3390\/v14081711","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]}}}